pLKO-p53-shRNA-941 Citations (10)
Originally described in: Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.Kim JS, Lee C, Bonifant CL, Ressom H, Waldman T Mol Cell Biol. 2007 Jan . 27(2):662-77. PubMed Journal
Articles Citing pLKO-p53-shRNA-941
| Articles |
|---|
| Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1. Duan L, Perez RE, Hansen M, Gitelis S, Maki CG. Cancer Biol Ther. 2014;15(12):1600-12. doi: 10.4161/15384047.2014.961876. PubMed |
| Small-molecule inhibitors of USP7 induce apoptosis through oxidative and endoplasmic reticulum stress in cancer cells. Lee G, Oh TI, Um KB, Yoon H, Son J, Kim BM, Kim HI, Kim H, Kim YJ, Lee CS, Lim JH. Biochem Biophys Res Commun. 2016 Jan 29;470(1):181-6. doi: 10.1016/j.bbrc.2016.01.021. Epub 2016 Jan 6. PubMed |
| ATR Kinase Inhibition Protects Non-cycling Cells from the Lethal Effects of DNA Damage and Transcription Stress. Kemp MG, Sancar A. J Biol Chem. 2016 Apr 22;291(17):9330-42. doi: 10.1074/jbc.M116.719740. Epub 2016 Mar 3. PubMed |
| Cancer cell-secreted IGF2 instigates fibroblasts and bone marrow-derived vascular progenitor cells to promote cancer progression. Xu WW, Li B, Guan XY, Chung SK, Wang Y, Yip YL, Law SY, Chan KT, Lee NP, Chan KW, Xu LY, Li EM, Tsao SW, He QY, Cheung AL. Nat Commun. 2017 Feb 10;8:14399. doi: 10.1038/ncomms14399. PubMed |
| Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response. Park DE, Cheng J, Berrios C, Montero J, Cortes-Cros M, Ferretti S, Arora R, Tillgren ML, Gokhale PC, DeCaprio JA. Proc Natl Acad Sci U S A. 2019 Jan 15;116(3):1027-1032. doi: 10.1073/pnas.1818798116. Epub 2018 Dec 31. PubMed |
| Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity. Aho ER, Wang J, Gogliotti RD, Howard GC, Phan J, Acharya P, Macdonald JD, Cheng K, Lorey SL, Lu B, Wenzel S, Foshage AM, Alvarado J, Wang F, Shaw JG, Zhao B, Weissmiller AM, Thomas LR, Vakoc CR, Hall MD, Hiebert SW, Liu Q, Stauffer SR, Fesik SW, Tansey WP. Cell Rep. 2019 Mar 12;26(11):2916-2928.e13. doi: 10.1016/j.celrep.2019.02.047. PubMed |
| WDR5 is a conserved regulator of protein synthesis gene expression. Bryan AF, Wang J, Howard GC, Guarnaccia AD, Woodley CM, Aho ER, Rellinger EJ, Matlock BK, Flaherty DK, Lorey SL, Chung DH, Fesik SW, Liu Q, Weissmiller AM, Tansey WP. Nucleic Acids Res. 2020 Apr 6;48(6):2924-2941. doi: 10.1093/nar/gkaa051. PubMed |
| The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Singh N, Ramnarine VR, Song JH, Pandey R, Padi SKR, Nouri M, Olive V, Kobelev M, Okumura K, McCarthy D, Hanna MM, Mukherjee P, Sun B, Lee BR, Parker JB, Chakravarti D, Warfel NA, Zhou M, Bearss JJ, Gibb EA, Alshalalfa M, Karnes RJ, Small EJ, Aggarwal R, Feng F, Wang Y, Buttyan R, Zoubeidi A, Rubin M, Gleave M, Slack FJ, Davicioni E, Beltran H, Collins C, Kraft AS. Nat Commun. 2021 Dec 21;12(1):7349. doi: 10.1038/s41467-021-26901-9. PubMed |
| Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells. Florian AC, Woodley CM, Wang J, Grieb BC, Slota MJ, Guerrazzi K, Hsu CY, Matlock BK, Flaherty DK, Lorey SL, Fesik SW, Howard GC, Liu Q, Weissmiller AM, Tansey WP. NAR Cancer. 2022 Mar 3;4(1):zcac007. doi: 10.1093/narcan/zcac007. eCollection 2022 Mar. PubMed |
| Impact of p53 knockdown on protein dataset of HaCaT cells. Romashin DD, Rusanov AL, Kozhin PM, Karagyaur MN, Tikhonova OV, Zgoda VG, Luzgina NG. Data Brief. 2022 May 15;42:108274. doi: 10.1016/j.dib.2022.108274. eCollection 2022 Jun. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.